Coulter Pharmaceuticals Inc., of South San Francisco, received U.S. Patent No. 6,090,365 covering antibody therapy for treatment of lymphoma.
Cytochroma Inc., of Kingston, Ontario, received U.S. Patent No. 6,063,608 titled "Retinoid Metabolizing Protein." It covers a novel retinoic acid-inducible cytochrome named P450RAI.
Dendreon Corp., of Seattle, received U.S. Patent No. 6,080,049 titled "Immunostimulatory Composition." It covers the method by which Dendreon's vaccines stimulate the T-cell arm of the immune system to fight cancer.
GenVac Inc., of Gaithersburg, Md., received a U.S. patent covering replication-deficient adenovectors.
Incara Pharmaceuticals Corp., of Research Triangle Park, N.C., received a U.S. patent titled "Oxidoreductase Activity of Maganic Porphrins." It covers a novel mechanism of action for small molecules acting as catalytic antitoxidants.
Lynx Therapeutics Inc., of Hayward, Calif., received two U.S. patents covering any mixture of microbeads constructed to carry multiple copies of one of many different DNA fragments and any set of oligonucleotides that differ by at least two bases and form duplexes of equivalent stability under stringent hybridization conditions.
Magainin Pharmaceuticals Inc., of Plymouth Meeting, Pa., received a U.S. patent covering the use, formulation and administration of a novel aminosterol, MSI-1436.
Martek Biosciences Corp., of Columbia, Md., received U.S. Patent No. 6,111,066 covering technology related to rapid determination of 3-D protein structures.
Maxygen Inc., of Redwood City, Calif., received U.S. Patent No. 6,117,679 covering in vivo DNAShuffling recombination methods and formats.